摘要
In recent years,the clustered regularly interspaced short palindromic repeats-associated protein 9(CRISPR-Cas9)technology that won the 2020 Nobel Prize in Chemistry has served as one of the most prominent and powerful tools in gene editing for biomedical research and the treatment of various diseases[1].Nevertheless,it remains a substantial challenge to effectively and safely deliver CRISPR-Cas9 molecules into target cells[2].
作者
Lifang Ma
Caihong Dong
Meihua Yu
Xinran Song
Yongchun Yu
Yu Chen
马丽芳;董彩虹;余美华;宋新然;于永春;陈雨(Shanghai Institute of Thoracic Oncology,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Clinical Laboratory Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Ultrasound,Zhongshan Hospital,Fudan University,and Shanghai Institute of Medical Imaging,Shanghai 200032,China;Materdicine Laboratory,School of Life Sciences,Shanghai University,Shanghai 200444,China)
基金
supported by the National Key R&D Program of China(2016YFA0203700)
the National Natural Science Foundation of China(51672303,81902315,82102085,32101146)
Excellent Talents Nurture Project of Shanghai Chest Hospital(2021YNZYY02)
International Collaboration Project of Chinese Academy of Sciences(GJHZ2072)
financial support from Science and Technology Development Fund of Shanghai Chest Hospital
financial support from Talent Training Plan of Shanghai Chest Hospital in 2020。
